Evidence map›Paper›PMID 34870835›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Generation of Pericytic-Vascular Progenitors from Tankyrase/PARP-Inhibitor-Regulated Naïve (TIRN) Human Pluripotent Stem Cells.

Ludovic Zimmerlin, Tea Soon Park, Imran Bhutto, Gerard Lutty, Elias T Zambidis

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ludovic ZimmerlinSidney Kimmel Comprehensive Cancer Center, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tea Soon ParkSidney Kimmel Comprehensive Cancer Center, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Imran BhuttoSidney Kimmel Comprehensive Cancer Center, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gerard LuttySidney Kimmel Comprehensive Cancer Center, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Elias T ZambidisSidney Kimmel Comprehensive Cancer Center, Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. ezambid1@jhmi.edu.
Sidney Kimmel Comprehensive Cancer Center · USJohns Hopkins University · US

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI JEFFREY MUMM · 1985 to 2026
$22.1M
Inflammatory cells of choroid: a therapeutic target in AMD.R01EY016151 · NEI · JOHNS HOPKINS UNIVERSITY · PI EDWARDS, MALIA MICHELLE · 2006 to 2024
$8.0M
Embryonic vascular stem-progenitors for treatment of ischemic retinopathiesR01EY032113 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2021 to 2024
$2.0M
Pluripotent Stem Cell Vascular Therapies for Ischemic RetinopathiesR01EY023962 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2014 to 2018
$1.8M
Functional Vascular Progenitors from Naive Human iPSCR01HD082098 · NICHD · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2015 to 2019
$1.7M
NEI NIH HHS P30 EY001765NEI NIH HHS R01 EY016151NEI NIH HHS R01 EY023962NEI NIH HHS R01 EY032113NICHD NIH HHS R01 HD082098
6 · The paper itself

Abstract

Tankyrase/PARP inhibitor-regulated naïve human pluripotent stem cells (TIRN-hPSC) represent a new class of human stem cells for regenerative medicine that can differentiate into multi-lineage progenitors with improved in vivo functionality. Chemical reversion of conventional, primed hPSC to a TIRN-hPSC state alleviates dysfunctional epigenetic donor cell memory, lineage-primed gene expression, and potentially disease-associated aberrations in their differentiated progeny. Here, we provide methods for the reversion of normal or diseased patient-specific primed hPSC to TIRN-hPSC and describe their subsequent differentiation into embryonic-like pericytic-endothelial "naïve" vascular progenitors (N-VP). N-VP possess improved vascular functionality, high epigenetic plasticity, maintain greater genomic stability, and are more efficient in migrating to and re-vascularizing ischemic tissues than those generated from primed isogenic hPSC. We also describe detailed methods for the ocular transplantation and quantitation of vascular engraftment of N-VP into the ischemia-damaged neural retina of a humanized mouse model of ischemic retinopathy. The application of TIRN-hPSC-derived N-VP will advance vascular cell therapies of ischemic retinopathy, myocardial infarction, and cerebral vascular stroke.

Indexed as

Pluripotent Stem CellsAnimalsCell DifferentiationHumansIschemiaMicePoly(ADP-ribose) Polymerase InhibitorsRetinal DiseasesTankyrasesPoly(ADP-ribose) Polymerase InhibitorsTankyrasesDifferentiationHuman pluripotent stem cellIschemic retinopathyNaïve pluripotencyPARPPericyteTankyrase inhibitionVascular progenitorsVascular regeneration

Identifiers

PMID34870835
PMCPMC9529319
OpenAlexW4200231935

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.